Voxzogo (Vosoritide) Patent Expiration, LOE Window & CMS Spending

Voxzogo (Vosoritide) by BioMarin Pharmaceutical: FDA Orange Book core substance LOE 2035-06-11 (last listed 2042-07-11), 0 AB generics, $57.2M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBioMarin Pharmaceutical
FDA Application & PathwayN214938 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2035-06-11
Last Listed Patent or Exclusivity Date2042-07-11
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$57.2M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$57.2M
Reported Wholesale Price Change (CA SB 17)9 WAC filings (max 21.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for BioMarin Pharmaceutical across sibling Meru public-data platforms.